Evidence map›Paper›PMID 33057670›Full record

Trial reportSchizophrenia bulletin2021

Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study.

Paola Dazzan, Andrew J Lawrence, Antje A T S Reinders, Alice Egerton, Neeltje E M van Haren, Kate Merritt, Gareth J Barker, Rocio Perez-Iglesias, Kyra-Verena Sendt, Arsime Demjaha and 23 more

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Schizophrenia bulletin, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Longitudinal Allometry of Sulcal Morphology in Health and Schizophrenia.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 14 institutions in 9 countries.

Paola DazzanDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Andrew J LawrenceDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Antje A T S ReindersDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Alice EgertonNational Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
Neeltje E M van HarenDepartment of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, The Netherlands.
Kate MerrittNational Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
Gareth J BarkerCentre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Rocio Perez-IglesiasEarly Intervention in Psychosis Service, Department of Psychiatry, Hospital Universitario Marques de Valdecilla, Santander, Spain.
Kyra-Verena SendtNational Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
Arsime DemjahaNational Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
Kie W NamNational Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
Iris E SommerDepartment of Biomedical Sciences of Cells and Systems, Rijksuniversiteit Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Christos PantelisMelbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Carlton South, Victoria, Australia.
W Wolfgang FleischhackerMedical University of Innsbruck, Department of Psychiatry, Psychotherapy and Psychosomatics, Division of Psychiatry I, Innsbruck, Austria.
Inge Winter van RossumCentre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Silvana GalderisiDepartment of Psychiatry, University of Campania Luigi Vanvitelli, Naples, Italy.
Armida MucciDepartment of Psychiatry, University of Campania Luigi Vanvitelli, Naples, Italy.
Richard DrakeDivision of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.
Shon LewisDivision of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.
Mark WeiserDepartment of Psychiatry, Sheba Medical Center, Tel Aviv, Israel.
Covadonga M Martinez Diaz-CanejaDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañon, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense Madrid, Madrid, Spain.
Joost JanssenDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañon, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense Madrid, Madrid, Spain.
Marina Diaz-MarsaDepartment of Psychiatry, Instituto de Investigación Sanitaria Hospital Clínico San Carlos; CIBERSAM; Universidad Complutense Madrid, Madrid, Spain.
Roberto Rodríguez-JimenezDepartment of Psychiatry, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12); CIBERSAM; Universidad Complutense Madrid, Madrid, Spain.
Celso ArangoDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañon, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense Madrid, Madrid, Spain.
Lone BaandrupCenter for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Copenhagen, Denmark.
Brian BrobergCenter for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Copenhagen, Denmark.
Egill RostrupCenter for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Copenhagen, Denmark.
Bjørn H EbdrupCenter for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Copenhagen, Denmark.
Birte GlenthøjCenter for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Copenhagen, Denmark.
Rene S KahnDepartment of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.
Philip McGuireNational Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
OPTiMiSE study group
King's College London · GBUniversity of Copenhagen · DKHospital General Universitario Gregorio Marañón · ESManchester Academic Health Science Centre · GBUniversity of Campania "Luigi Vanvitelli" · ITUtrecht University · NLWellcome Centre for Human Neuroimaging · GBCentro de Investigación Biomédica en Red de Salud Mental · ESHospital Clínico San Carlos · ESInnsbruck Medical University · ATMarqués de Valdecilla University Hospital · ESTel Aviv University · ILThe University of Melbourne · AUUniversity Medical Center Groningen · NL

Funding

Medical Research Council MC_PC_11003Medical Research Council MR/S003444/1MRF_ C0439
6 · The paper itself

Abstract

Individuals with psychoses have brain alterations, particularly in frontal and temporal cortices, that may be particularly prominent, already at illness onset, in those more likely to have poorer symptom remission following treatment with the first antipsychotic. The identification of strong neuroanatomical markers of symptom remission could thus facilitate stratification and individualized treatment of patients with schizophrenia. We used magnetic resonance imaging at baseline to examine brain regional and network correlates of subsequent symptomatic remission in 167 medication-naïve or minimally treated patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder entering a three-phase trial, at seven sites. Patients in remission at the end of each phase were randomized to treatment as usual, with or without an adjunctive psycho-social intervention for medication adherence. The final follow-up visit was at 74 weeks. A total of 108 patients (70%) were in remission at Week 4, 85 (55%) at Week 22, and 97 (63%) at Week 74. We found no baseline regional differences in volumes, cortical thickness, surface area, or local gyrification between patients who did or did not achieved remission at any time point. However, patients not in remission at Week 74, at baseline showed reduced structural connectivity across frontal, anterior cingulate, and insular cortices. A similar pattern was evident in patients not in remission at Week 4 and Week 22, although not significantly. Lack of symptom remission in first-episode psychosis is not associated with regional brain alterations at illness onset. Instead, when the illness becomes a stable entity, its association with the altered organization of cortical gyrification becomes more defined.

Indexed as

Outcome Assessment, Health CarePsychotic DisordersSchizophreniaAdolescentAdultAntipsychotic AgentsCerebral CortexFemaleFollow-Up StudiesHumansMagnetic Resonance ImagingMaleNerve NetRemission InductionTime FactorsYoung AdultAntipsychotic Agentscortical thicknessfirst episodegyrificationMRIOPTiMiSEschizophreniatrial

Identifiers

PMID33057670
PMCPMC7965060
OpenAlexW3089176224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.